129 related articles for article (PubMed ID: 38683548)
21. Pulmonary drug delivery: a role for polymeric nanoparticles?
d'Angelo I; Conte C; Miro A; Quaglia F; Ungaro F
Curr Top Med Chem; 2015; 15(4):386-400. PubMed ID: 25579350
[TBL] [Abstract][Full Text] [Related]
22. Development of Inhalable Nanostructured Lipid Carriers for Ciprofloxacin for Noncystic Fibrosis Bronchiectasis Treatment.
Almurshedi AS; Aljunaidel HA; Alquadeib B; Aldosari BN; Alfagih IM; Almarshidy SS; Eltahir EKD; Mohamoud AZ
Int J Nanomedicine; 2021; 16():2405-2417. PubMed ID: 33814907
[TBL] [Abstract][Full Text] [Related]
23. Uptake and transfection with polymeric nanoparticles are dependent on polymer end-group structure, but largely independent of nanoparticle physical and chemical properties.
Sunshine JC; Peng DY; Green JJ
Mol Pharm; 2012 Nov; 9(11):3375-83. PubMed ID: 22970908
[TBL] [Abstract][Full Text] [Related]
24. Inhalable polymer-glycerosomes as safe and effective carriers for rifampicin delivery to the lungs.
Melis V; Manca ML; Bullita E; Tamburini E; Castangia I; Cardia MC; Valenti D; Fadda AM; Peris JE; Manconi M
Colloids Surf B Biointerfaces; 2016 Jul; 143():301-308. PubMed ID: 27022870
[TBL] [Abstract][Full Text] [Related]
25. Polymer-Based Novel Lung Targeted Delivery Systems.
Elmowafy E; Osman R; Ishak RA
Curr Pharm Des; 2017; 23(3):373-392. PubMed ID: 27799039
[TBL] [Abstract][Full Text] [Related]
26. Inhalable, bioresponsive microparticles for targeted drug delivery in the lungs.
Sivadas N; Cryan SA
J Pharm Pharmacol; 2011 Mar; 63(3):369-75. PubMed ID: 21749384
[TBL] [Abstract][Full Text] [Related]
27. Polymer-lipid hybrid systems used as carriers for insulin delivery.
Grigoras AG
Nanomedicine; 2017 Nov; 13(8):2425-2437. PubMed ID: 28821465
[TBL] [Abstract][Full Text] [Related]
28. Albumin-micelles via a one-pot technology platform for the delivery of drugs.
Jiang Y; Liang M; Svejkar D; Hart-Smith G; Lu H; Scarano W; Stenzel MH
Chem Commun (Camb); 2014 Jun; 50(48):6394-7. PubMed ID: 24811583
[TBL] [Abstract][Full Text] [Related]
29. Delivery strategies for sustained drug release in the lungs.
Loira-Pastoriza C; Todoroff J; Vanbever R
Adv Drug Deliv Rev; 2014 Aug; 75():81-91. PubMed ID: 24915637
[TBL] [Abstract][Full Text] [Related]
30. Dynamic mucus penetrating microspheres for efficient pulmonary delivery and enhanced efficacy of host defence peptide (HDP) in experimental tuberculosis.
Sharma A; Vaghasiya K; Gupta P; Singh AK; Gupta UD; Verma RK
J Control Release; 2020 Aug; 324():17-33. PubMed ID: 32418903
[TBL] [Abstract][Full Text] [Related]
31. A comparison of the lung clearance kinetics of solid lipid nanoparticles and liposomes by following the
Haque S; Whittaker M; McIntosh MP; Pouton CW; Phipps S; Kaminskas LM
Eur J Pharm Biopharm; 2018 Apr; 125():1-12. PubMed ID: 29309835
[TBL] [Abstract][Full Text] [Related]
32. Inhalable multi-compartmental phospholipid enveloped lipid core nanocomposites for localized mTOR inhibitor/herbal combined therapy of lung carcinoma.
Kabary DM; Helmy MW; Abdelfattah EA; Fang JY; Elkhodairy KA; Elzoghby AO
Eur J Pharm Biopharm; 2018 Sep; 130():152-164. PubMed ID: 29964122
[TBL] [Abstract][Full Text] [Related]
33. Multilayer affinity adsorption of albumin on polymer brushes modified membranes in a continuous-flow system.
Hu MX; Li X; Li JN; Huang JJ; Ren GR
J Chromatogr A; 2018 Feb; 1538():94-103. PubMed ID: 29370921
[TBL] [Abstract][Full Text] [Related]
34. Role of stealth lipids in nanomedicine-based drug carriers.
Rastogi M; Saha RN; Alexander A; Singhvi G; Puri A; Dubey SK
Chem Phys Lipids; 2021 Mar; 235():105036. PubMed ID: 33412151
[TBL] [Abstract][Full Text] [Related]
35. Hybrid Lipid/Polymer Nanoparticles to Tackle the Cystic Fibrosis Mucus Barrier in siRNA Delivery to the Lungs: Does PEGylation Make the Difference?
Conte G; Costabile G; Baldassi D; Rondelli V; Bassi R; Colombo D; Linardos G; Fiscarelli EV; Sorrentino R; Miro A; Quaglia F; Brocca P; d'Angelo I; Merkel OM; Ungaro F
ACS Appl Mater Interfaces; 2022 Feb; 14(6):7565-7578. PubMed ID: 35107987
[TBL] [Abstract][Full Text] [Related]
36. Antibiotic-free nanotherapeutics: ultra-small, mucus-penetrating solid lipid nanoparticles enhance the pulmonary delivery and anti-virulence efficacy of novel quorum sensing inhibitors.
Nafee N; Husari A; Maurer CK; Lu C; de Rossi C; Steinbach A; Hartmann RW; Lehr CM; Schneider M
J Control Release; 2014 Oct; 192():131-40. PubMed ID: 24997276
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic advantage of inhaled tacrolimus-bound albumin nanoparticles in a bleomycin-induced pulmonary fibrosis mouse model.
Seo J; Lee C; Hwang HS; Kim B; Thao le Q; Lee ES; Oh KT; Lim JL; Choi HG; Youn YS
Pulm Pharmacol Ther; 2016 Feb; 36():53-61. PubMed ID: 26768967
[TBL] [Abstract][Full Text] [Related]
38. Lipid-based pulmonary delivery system: a review and future considerations of formulation strategies and limitations.
Ngan CL; Asmawi AA
Drug Deliv Transl Res; 2018 Oct; 8(5):1527-1544. PubMed ID: 29881970
[TBL] [Abstract][Full Text] [Related]
39. Chain-extension in hyperbranched polymers alters tissue distribution and cytotoxicity profiles in orthotopic models of triple negative breast cancers.
Moloney C; Mehradnia F; Cavanagh RJ; Ibrahim A; Pearce AK; Ritchie AA; Clarke P; Rahman R; Grabowska AM; Alexander C
Biomater Sci; 2023 Sep; 11(19):6545-6560. PubMed ID: 37593851
[TBL] [Abstract][Full Text] [Related]
40. Translatable High Drug Loading Drug Delivery Systems Based on Biocompatible Polymer Nanocarriers.
Chen W; Zhou S; Ge L; Wu W; Jiang X
Biomacromolecules; 2018 Jun; 19(6):1732-1745. PubMed ID: 29690764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
